pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Radioligand Therapy · news · pharmadog
← back to Radioligand Therapy
News · Radioligand Therapy
133
stories
5d
3 steps for taking on Novartis in radiopharma: Curium up first
biospace
10d
How radioligand therapy is rewriting cancer care
biospace
11d
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
biospace
12d
Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal
endpoints
12d
Novartis secures new radioligand in $900M deal as competition strengthens
fiercebiotech
13d
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
biospace
13d
Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
biospace
13d
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
13d
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
biopharma dive
13d
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
fiercebiotech
14d
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
19d
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
19d
FDA approves first radioligand generic, setting up rivalry with Novartis
endpoints
21d
GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times
fiercebiotech
24d
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
24d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Aug 31, 26
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
Aug 25, 26
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 12, 26
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
Aug 11, 26
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
biospace
Aug 11, 26
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
stat
Aug 11, 26
Recon: FDA rejects ITM radiopharma therapy; WHO defends immunization schedules
raps
Aug 10, 26
FDA rejects ITM's radiopharma drug over manufacturing problems
endpoints
Aug 10, 26
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
Aug 4, 26
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
Aug 3, 26
FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
endpoints
Aug 3, 26
Curium buys radiopharma rival Lantheus for $8B; Sandoz settles price-fixing case
endpoints
Aug 3, 26
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
← prev
page 1 of 5
next →
